NYSE:DNA) Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors ...

Pathologic Complete Response reported for 2 patients with cutaneous Squamous Cell CarcinomaMarlborough, Massachusetts--(Newsfile Corp. - January ...

Personalized Medicine : By combining iPSCs with genome-editing technologies like CRISPR, scientists can introduce precise genetic modifications, such as knock-outs, knock-ins, or single base changes, ...

Korean company, top stakeholder of Norwegian firm, silent on closure of US plant Hanwha is facing strong opposition from ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25Deepening responses observed over time in ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.

Presented updated clinical and biomarker activity data at the IOVC in October 2024. Investigators reported ongoing improved ...

The company had $583.3 million in cash as of September 30th of 2024; Enough cash to fund its operations until the end of 2027 ...

Werewolf Therapeutics, Inc. (the "Company” or "Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering ...

"It was in banking that I finally realized why the internet sucked," says Rohit Jha, co-founder and CEO of Transcelestial.

NDAQ:KYTX) Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference ...

Cerebral vascular malformations (CVMs), including cerebral arteriovenous malformations (AVMs) and cavernous malformations (CCMs), have long posed challenges due to their complex origins and severe ...